Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT)’s traded shares stood at 0.44 million during the last session, with the company’s beta value hitting 2.97. At the close of trading, the stock’s price was $16.19, to imply a decrease of -6.36% or -$1.1 in intraday trading. The ARCT share’s 52-week high remains $45.00, putting it -177.95% down since that peak but still an impressive 11.67% since price per share fell to its 52-week low of $14.30. The company has a valuation of $438.54M, with an average of 0.42 million shares in intraday trading volume over the past 10 days and average of 426.55K shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Arcturus Therapeutics Holdings Inc (ARCT), translating to a mean rating of 1.00. Of 6 analyst(s) looking at the stock, 1 analyst(s) give ARCT a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 5 recommend it as a Buy.
Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) trade information
After registering a -6.36% downside in the last session, Arcturus Therapeutics Holdings Inc (ARCT) has traded red over the past five days. The 5-day price performance for the stock is -4.60%, and -22.28% over 30 days. With these gigs, the year-to-date price performance is -4.60%. Short interest in Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) saw shorts transact 5.04 million shares and set a 11.98 days time to cover.
The extremes give us $10.58 and $10.58 for target low and target high price respectively. As such, ARCT has been trading 34.65% off suggested target high and 34.65% from its likely low.
ARCT Dividends
Arcturus Therapeutics Holdings Inc has its next earnings report out in March. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT)’s Major holders
Arcturus Therapeutics Holdings Inc insiders hold 8.46% of total outstanding shares, with institutional holders owning 88.60% of the shares at 96.78% float percentage. In total, 88.60% institutions holds shares in the company, led by FEDERATED HERMES, INC.. As of 2024-06-30, the company held over 4.69 million shares (or 17.4067% of shares), all amounting to roughly $114.3 million.
The next major institution holding the largest number of shares is BLACKROCK INC. with 2.65 million shares, or about 9.8262% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $64.52 million.
We also have Federated Hermes Kaufmann Fund and Federated Hermes Kaufmann Small Cap Fund as the top two Mutual Funds with the largest holdings of the Arcturus Therapeutics Holdings Inc (ARCT) shares. Going by data provided on Oct 31, 2024 , Federated Hermes Kaufmann Fund holds roughly 2.44 shares. This is just over 8.99% of the total shares, with a market valuation of $39.44 million. Data from the same date shows that the other fund manager holds a little less at 2.2, or 8.11% of the shares, all valued at about 35.59 million.
